Matthew Gall
CIK: 0001816194
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (11 total)
- May 1, 2026TNGX
Tango Therapeutics, Inc.
Award(A)Direct40K shares- - Mar 19, 2026KLRS
Kalaris Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
95K shares- - Nov 3, 2025KLRS
Kalaris Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
235K shares- - Aug 29, 2025ITOS
iTeos Therapeutics, Inc.
Disposition(D)DirectStock Option (Right to Buy)
252.1K shares- - Aug 29, 2025ITOS
iTeos Therapeutics, Inc.
Disposition(D)DirectStock Option (Right to Buy)
8.1K shares- - Aug 29, 2025ITOS
iTeos Therapeutics, Inc.
Tender Offer(U)Direct89.4K shares- - Aug 29, 2025ITOS
iTeos Therapeutics, Inc.
Disposition(D)DirectStock Option (Right to Buy)
9.1K shares- - Aug 29, 2025ITOS
iTeos Therapeutics, Inc.
Disposition(D)DirectStock Option (Right to Buy)
135.9K shares- - Aug 29, 2025ITOS
iTeos Therapeutics, Inc.
Disposition(D)DirectStock Option (Right to Buy)
42.4K shares- - Mar 7, 2025ITOS
iTeos Therapeutics, Inc.
Award(A)Direct24K shares- - Nov 19, 2024ITOS
iTeos Therapeutics, Inc.
Purchase(P)Direct5K shares at avg. $7.73$39K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| May 1, 2026 |  TNGX Tango Therapeutics, Inc. | Award(A) | 40,000 | - | $0 | Direct |
| Mar 19, 2026 |  KLRS Kalaris Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 95,000 | - | - | Direct |
| Nov 3, 2025 | KLRS Kalaris Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 235,000 | - | - | Direct |
| Aug 29, 2025 |  ITOS iTeos Therapeutics, Inc. | Disposition(D) Stock Option (Right to Buy) | 252,135 | - | - | Direct |
| Aug 29, 2025 | ITOS iTeos Therapeutics, Inc. | Disposition(D) Stock Option (Right to Buy) | 8,123 | - | - | Direct |
| Aug 29, 2025 | ITOS iTeos Therapeutics, Inc. | Tender Offer(U) | 89,429 | - | - | Direct |
| Aug 29, 2025 | ITOS iTeos Therapeutics, Inc. | Disposition(D) Stock Option (Right to Buy) | 9,063 | - | - | Direct |
| Aug 29, 2025 | ITOS iTeos Therapeutics, Inc. | Disposition(D) Stock Option (Right to Buy) | 135,937 | - | - | Direct |
| Aug 29, 2025 | ITOS iTeos Therapeutics, Inc. | Disposition(D) Stock Option (Right to Buy) | 42,388 | - | - | Direct |
| Mar 7, 2025 | ITOS iTeos Therapeutics, Inc. | Award(A) | 24,000 | - | - | Direct |
| Nov 19, 2024 | ITOS iTeos Therapeutics, Inc. | Purchase(P) | 5,000 | $7.73 | $38,635 | Direct |
1-11 of 11 transactions
About Gall Matthew
Gall Matthew (SEC CIK 0001816194) files insider reports with the SEC as Chief Financial Officer of Tango Therapeutics, Inc. (TNGX), Chief Financial Officer of Kalaris Therapeutics, Inc. (KLRS) and Chief Financial Officer of iTeos Therapeutics, Inc. (ITOS).
Signal8 holds 8 ownership filings by Gall Matthew (2 Form 3, 6 Form 4), filed between Nov 19, 2024 and May 5, 2026. Those filings report 11 transactions, from Nov 19, 2024 to May 1, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Gall Matthew's filings is in BERKELEY HEIGHTS, NJ.
Recent filings by Gall Matthew
- May 1, 2026: Grant or award of TNGX shares (Form 4, code A).
- Mar 19, 2026: Grant or award of KLRS derivative securities (Form 4, code A).
- Nov 3, 2025: Grant or award of KLRS derivative securities (Form 4, code A).
- Aug 29, 2025: Disposition to issuer transactions of ITOS derivative securities (2 lines, Form 4, code D).
- Aug 29, 2025: Tender of shares transaction of ITOS shares (Form 4, code U).
Other insiders filing for Tango Therapeutics, Inc. (TNGX)
- Crystal Adam, President, R&D
- Newcomb Jessica, Principal Accounting Officer
- Azelby Robert, Director
- Ketchum John B, Director
- Calhoun Lesley Ann, Director
- Rothenberg Mace, Director